Teva Bids to Acquire BioXcel's Dexmedetomidine Sublingual Film for At-Home Agitation Treatment
核心洞察
Teva announced a stalking horse bid to acquire BioXcel Therapeutics' dexmedetomidine sublingual film (BXCL501/IGALMI) through a court-supervised bankruptcy sale process.
The investigational film is under FDA review for at-home treatment of agitation associated with schizophrenia (搜索) or bipolar I or II disorder, with a PDUFA date of November 14, 2026.
The transaction carries an upfront payment of $57.5 million plus up to $67.5 million in contingent payments, and remains subject to bankruptcy court approval and potential higher bids.
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced on August 28, 2026 that it has made a bid to acquire an innovative neuroscience product from BioXcel Therapeutics, Inc. through a court-supervised sale process. The novel dexmedetomidine sublingual film is under U.S. Food and Drug Administration (FDA) review for potential at-home use for the acute treatment of agitation associated with schizophrenia (搜索) or bipolar I or II disorder in adults. If approved, it could become the first FDA-approved at-home treatment for this condition.
"Business development plays a critical role in accelerating our Pivot to Growth strategy," said Evan Lippman, Executive Vice President, Business Development at Teva. "This opportunity strengthens our neuroscience portfolio and reflects our disciplined approach to pursuing innovative assets with a clear strategic fit, the potential to make a meaningful difference for patients and attractive long-term growth potential, while balancing risk and value creation."
Unmet Need in Agitation Management
For people living with schizophrenia (搜索) or bipolar I or II disorder, agitation episodes can be unpredictable, disruptive, and distressing for patients, families, and caregivers. In some cases, these episodes may lead to escalation of care, including emergency department visits or hospitalization. Despite this burden, acute treatment options specifically designed for agitation remain limited, particularly options that may be used outside healthcare and hospital settings.
The Proposed Transaction
Teva has entered into an agreement with BioXcel Therapeutics, Inc. to serve as the "stalking horse bidder" in a court-supervised auction process, pursuant to Section 363 of Chapter 11 of the U.S. Bankruptcy Code, for the purchase of certain assets from BioXcel Therapeutics and its affiliates, including IGALMI, its dexmedetomidine sublingual film. As the stalking horse bidder, Teva's proposal establishes the initial bid for the assets. The proposed transaction does not involve the acquisition of BioXcel Therapeutics as a whole.
Teva would acquire the agreed-upon assets if it is selected as the successful bidder during the auction, required conditions are satisfied, and the transaction is approved by the Bankruptcy Court. If Teva is not the successful bidder, it would be entitled to a break-up fee and expense reimbursement, subject to the terms of the agreement.
Under the terms of the agreement, Teva would acquire worldwide rights to the assets, including dexmedetomidine sublingual film, for an upfront payment of $57.5 million and up to an additional $67.5 million in contingent payments. These include a range of time-based payments linked to the timing of the pending FDA approval, including potential delays in approval, as well as payments tied to the achievement of specified sales milestones.
About Dexmedetomidine Sublingual Film (BXCL501)
Dexmedetomidine is a selective alpha-2 adrenergic receptor (搜索) agonist. Dexmedetomidine sublingual film is a proprietary, investigational, orally dissolving film formulation currently under FDA review for at-home use in the acute treatment of agitation associated with schizophrenia (搜索) or bipolar I or II disorder in adults. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 14, 2026.
About IGALMI
IGALMI (dexmedetomidine) sublingual film is a prescription medicine, administered under the supervision of a healthcare provider, which is placed under the tongue or behind the lower lip and is used for the acute treatment of agitation associated with schizophrenia (搜索) and bipolar disorder I or II in adults. The safety and effectiveness of IGALMI have not been studied beyond 24 hours from the first dose, and it is not known if IGALMI is safe and effective in children.
IGALMI can cause serious side effects, including decreased blood pressure, low blood pressure upon standing, and slower than normal heart rate, which may be more likely in patients with low blood volume, diabetes, chronic high blood pressure, and older patients. It can also cause heart rhythm changes (QT interval prolongation), and should not be given to patients with an abnormal heart rhythm, a history of an irregular heartbeat, slow heart rate, low potassium, low magnesium, or those taking other drugs that could affect heart rhythm. Taking IGALMI with a history of abnormal heart rhythm can increase the risk of torsades de pointes and sudden death.
Patients should not perform activities requiring mental alertness, such as driving or operating hazardous machinery, for at least 8 hours after taking IGALMI. Withdrawal reactions, tolerance, and decreased response or efficacy may occur if IGALMI is used longer than 24 hours. The most common side effects in clinical studies were sleepiness or drowsiness, a prickling or tingling sensation or numbness of the mouth, dizziness, dry mouth, low blood pressure, and low blood pressure upon standing.
Strategic Context
The transaction reflects Teva's targeted business development approach focused on strategic fit, patient needs, and potential long-term value. If completed, the asset would expand Teva's psychiatry portfolio and, pending FDA approval, could help address a meaningful unmet need for people living with complex mental health conditions. Guggenheim Securities, LLC served as financial advisors and Ropes & Gray LLP served as legal advisors to Teva.